Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Solid Tumour × nintedanib × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 2 Solid Tumors 1 Patients With Any Advanced Solid Tumors 1 Mesothelioma 1 Malignant Solid Tumour 1

Interventions

Vorinostat 2 pembrolizumab 1 nintedanib 1 dactolisib 1 avelumab 1 Vinorelbine 1 Sunitinib 1 Oxaliplatin 1 Levoleucovorin 1 Leucovorin 1 Hydroxychloroquine 1 Folfox protocol 1 Fluorouracil 1 Dasatinib 1 DOXO-EMCH 1 Cetuximab 1 Bevacizumab 1 BN 80927 1 ARQ 197 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Boehringer Ingelheim

Phase 1 Completed

Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡